Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn's and Colitis Organization (ECCO) annual congress investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Nine presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityFour new analyses from Phase 3 SELECTION and SELECTION long term extension studies of Jyseleca
Prometheus Biosciences to Host Virtual R&D Day for globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
(0)
LONDON, ON, April 14, 2021 /PRNewswire/ Alimentiv Health Trust, the parent company of Alimentiv, Inc. (formerly Robarts Clinical Trials), a specialized global gastrointestinal (GI) contract research organization (CRO), and McDougall Scientific Ltd., a niche CRO, announced today the launch of AcelaBio, a commercial state-of-the-art research laboratory delivering histopathology and precision medicine services for global clinical trials.
AcelaBio s primary focus is to accelerate biomarker discovery and development by providing end-to-end specialty histopathology & precision medicine services for global clinical trials. This state-of-the-art laboratory has strong synergies with Alimentiv (CRO) that will enhance the ability to deliver clinical research to pharmaceutical and biotech industry partners.
Erin Whitney as head of global clinical operations and
Keith White as head of global market access and has also appointed brand strategy consultant
Shauna Horvath to head of global marketing. Whitney joins the team from bluebird bio, while Merck and Genentech veteran White was most recently VP, global market access and pricing at Corbus Pharmaceuticals. Horvath joined Amylyx as a consultant in 2019.
> Culver City, California’s ImmunityBio tapped
Fabio M. Benedetti, M.D., as chief strategy officer, effective Jan. 4. Should ImmunityBio’s NantKwest merger close, Benedetti is expected to assume the role of CSO at the combined company, ImmunityBio said. Benedetti joins from combination therapy specialist Apollomics, where he was chief medical officer.